Shares shifted sharply higher as analyst upgrades and lifted price targets injected fresh confidence into Judges Scientific, a London-listed maker of niche scientific instruments now trading at £49.20 — up 16% in seven days. For a stock that peaked near £91.20 just a year ago, the question is whether this bounce marks the start of a real recovery or a dead-cat rally in a still-difficult market.
A Rough Year Made the Stock Cheap Enough to Upgrade
Jefferies double-downgraded Judges Scientific to "underperform" back in January 2026, slashing its price target to 4,015p from 7,380p. That sell call came near the bottom. The average 12-month analyst target now sits at £64.50, with all three covering analysts rating the stock a buy — implying roughly 51% upside from early-June levels. The about-face matters because it signals Wall Street believes the worst of the earnings downturn is priced in.
Earnings Are in a Trough, and That's the Bull Case
FY25 revenue grew 9% to £146 million, but organic growth was just 2% ex a major contract, as U.S. academic funding cuts hammered orders. Management guided 2026 EPS at 200–250p, assuming no U.S. recovery.
At the midpoint, shares trade at roughly 19× trough earnings — but against normalized EPS of £3.64–£3.75 seen in 2022–23, the stock sits closer to 11.5×. That gap is precisely why bulls see more than 40% annualized earnings growth as achievable once headwinds ease.
The CEO Transition Adds Execution Risk
Founder David Cicurel transitioned to non-executive chair in February 2026, with former business development director Tim Prestidge promoted to CEO.
Jefferies noted the company is in its longest stretch without an acquisition since 2021, though its strong balance sheet leaves room for value-adding deals. Judges' entire model — buying small scientific businesses cheaply and letting them run independently — hinges on deal flow resuming under new leadership.
U.S. Research Funding Is the Swing Factor
The company entered 2026 with year-to-date order intake down 17%, though U.S. research funding has since been restored by Congress.
Adjusted net debt fell to £42.6 million , giving the company financial cushion. But until those restored dollars start flowing into equipment purchases, the recovery thesis stays just that — a thesis.